Our Facilities
Headquartered in Martinsried near Munich, Coriolis Pharma supports global pharmaceutical and biotech partners with expert drug product development services. Our flexible, state-of-the-art, fit-for-service facilities allow the Coriolis Pharma team to serve the comprehensive drug product development, analytical service and manufacturing service needs of wide-ranging biotherapeutic modalities under R&D and GMP conditions.
Headquarters and Primary Operations
Our 6-floor main facility houses our primary analytical lab, storage, non-GMP manufacturing and lyophilization capabilities.
Our 6-floor main facility houses our primary analytical lab, storage, non-GMP manufacturing and lyophilization capabilities.
Facility Highlights
- 3,600+ sqm R&D and GMP lab space under biosafety levels 1 and 2
- 200+ analytical devices, including analytical ultracentrifugation (AUC)
- Lyophilization Center
- HPLC Center Lab space with movable benches for increased flexibility
- Automated filling line and manual filling capacities under aseptic conditions
- 3,600+ sqm R&D and GMP lab space under biosafety levels 1 and 2
- 200+ analytical devices, including analytical ultracentrifugation (AUC)
- Lyophilization Center
- HPLC Center Lab space with movable benches for increased flexibility
- Automated filling line and manual filling capacities under aseptic conditions
Featured Services Under R&D and GMP
- Developability assessment
- Preformulation screening
- Formulation development
- Stability studies
- In-use studies
- Particle analytics
- Lyophilization process development
- Comparability studies
- Release testing
- Tox study manufacturing
- Developability assessment
- Preformulation screening
- Formulation development
- Stability studies
- In-use studies
- Particle analytics
- Lyophilization process development
- Comparability studies
- Release testing
- Tox study manufacturing
Advanced Therapy and Medical Products (ATMPs) Facility
To meet the rapidly growing needs of gene and cell therapy developers, Coriolis debuted its ATMP facility in Q1 2022.
To meet the rapidly growing needs of gene and cell therapy developers, Coriolis debuted its ATMP facility in Q1 2022.
Facility Highlights
- 1,400+ sqm lab space under biosafety level 2
- 60+ analytical devices
- Particle Identification Center
- Lyophilization line
- Center for Cell Culture
- 1,400+ sqm lab space under biosafety level 2
- 60+ analytical devices
- Particle Identification Center
- Lyophilization line
- Center for Cell Culture
Featured Services Under R&D and GMP
- Formulation development
- Stability studies
- In-use studies
- Virus titration and quantification
- Particle characterization and identification
- Comparability studies
- Lyophilization development
- Formulation development
- Stability studies
- In-use studies
- Virus titration and quantification
- Particle characterization and identification
- Comparability studies
- Lyophilization development
U.S. Headquarters and Laboratory
With our presence in North Carolina, we are able to serve our North American clients even better, offering our core services quickly and efficiently on site
With our presence in North Carolina, we are able to serve our North American clients even better, offering our core services quickly and efficiently on site
Facility Highlights
- Located in the Research Triangle Park of North Carolina
- Particle Analysis Center
- Analytical Services and Liquid Formulation Development
- Located in the Research Triangle Park of North Carolina
- Particle Analysis Center
- Analytical Services and Liquid Formulation Development
Featured Services
- Particle characterization and identification
- In-use studies
- Additional services coming soon
- Particle characterization and identification
- In-use studies
- Additional services coming soon
Coriolis by the Numbers
Talk to Our Experts or Request a Quote
Our expert team is ready to answer your questions and guide you to the services best suited to your program’s modality, stage and challenge. If your needs are well-defined, we’ll begin the quotation process.